Answers are grounded in this paper and cite their sources.
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) affect adults worldwide and are causes of morbidity. While lifestyle modification remains in first-line therapy, interest has emerged in herbal agents with potential hepatometabolic effects. Evidence synthesis has been limited by heterogeneity in formulations and study quality. We conducted a systematic review and network meta-analysis (NMA) to compare the efficacy of herbal therapies in MASLD/MASH. Methods: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and International Prospective Register of Systematic Reviews registration (CRD420251157401), PubMed, Web of Science, EMBASE, and Cochrane were searched through September 2025 for randomized controlled trials evaluating herbal therapies or derivatives in adults with MASLD/MASH. The primary outcomes included alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and liver stiffness. Random-effects NMAs estimated mean differences (MDs) with 95% confidence intervals, with treatment ranking using surface under the cumulative ranking curve (SUCRA). Risk of bias was assessed using RoB 2.0, and certainty of evidence using Confidence in NMA. The secondary outcomes showed variable effects on steatosis and fibrosis indices without consistent metabolic significance. Conclusion: . This should involve standardized production, dose-finding studies, purity verification, and mainly long-term safety evaluation before any clinical integration.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: